Impact of monoclonal antibody therapy for head and neck cancer on end-of-life care utilization and costs.

William J BenjaminPratyusha YalamanchiJeremy M G TaylorNicholas R LenzeFrancis P WordenSteven B ChinnMichelle M Chen

Published in: Head & neck (2023)

mAB use is associated with higher emergency department utilization and health care costs potentially due to infusion-related and drug toxicity expenses.

Keyphrases

monoclonal antibody
emergency department
healthcare
low dose
adverse drug
oxidative stress
drug induced
health information